Kurma Partners
- Company typePrivate
- Founded2009
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Kurma Partners does
Kurma Partners is a Paris-based venture capital firm founded in 2009 that specializes in financing healthcare and biotechnology innovation across Europe. The firm has financed 72 companies and founded 25 companies since inception, focusing on company creation from European academic research — it partners with leading institutions including Institut Pasteur, Inserm Transfert, SATT Paris-Saclay, IRB Barcelona, VIB, and Cancer Research UK to identify disruptive discoveries and assemble the scientific, entrepreneurial, and capital resources required to spin out therapeutics, diagnostics, and medical-device companies.
Kurma Partners firmographics
Firmographics- Name
- Kurma Partners
- Legal name
- Kurma Partners
- Website
- http://www.kurmapartners.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Kurma Partners industry classification
Industry- Product category
- Venture Capital - Healthcare and Biotechnology
- NAICS
- Funds, Trusts, and Other Financial Vehicles (525), Other Investment Pools and Funds (5259)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Corporate Venture Studios & Incubators (Build/launch ventures) (FSANAHAC)
- akta.pro secondary industry
- Joint Venture CVC / Consortium Funds (Multi-corporate) (FSANAHAE)
Keywords
Where Kurma Partners is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Kurma Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Distribution channels1 record
Marketing channels4 records
Kurma Partners product offering
Product offeringCore offering
Kurma Partners is a Paris-based venture capital firm that finances healthcare and biotechnology innovation in Europe across the company lifecycle, from academic spin-out creation through growth capital. It manages multiple specialized fund vehicles (therapeutic Biofund series, Diagnostics franchise, Growth Opportunities Fund) totaling approximately €1 billion in assets under management, and operates the Argobio Studio startup launchpad in partnership with leading European research institutions to build biotech companies from scientific discoveries.
Product overview
Kurma Partners is a Paris-based venture capital firm and Eurazeo Group company that operates as a major player in European healthcare and biotechnology financing. The firm manages multiple specialized investment funds totaling €1 billion in assets under management across its franchises. Its core offering includes therapeutic venture funds (Biofund series), a healthtech diagnostics fund (Kurma Diagnostics), and a growth-stage fund (Kurma Growth Opportunities). Additionally, the firm operates Argobio Studio, a biotech startup launchpad in partnership with leading European research institutions. Since 2009, Kurma has financed 72 companies and founded 25 companies, leveraging partnerships with top European academic research centers including Institut Pasteur, INSERM, and Paris Saclay to transform disruptive scientific discoveries into cutting-edge medicines and medical devices.
Differentiator
Problem solved
Functional benefit
Brands
- Kurma Biofund: Therapeutic venture franchise investing from pre-seed stage to growth capital in life sciences companies
- Kurma Diagnostics
- Kurma Growth Opportunities Fund
- ArgoBio Studio
Products and services
- Kurma Biofund IV A €215 million venture capital fund focused on European biotech investments targeting disruptive therapeutic solutions for severe or incurable diseases, with approximately 80% allocated to therapy development and up to half directed toward companies established by Kurma or its ArgoBio Studio launchpad. Intended for institutional and strategic limited partners.
- Kurma Growth Opportunities Fund A growth-stage investment fund within Kurma Partners' franchise that supports later-stage European healthcare and biotech companies, with €160 million in first close commitments and a €250 million target. Intended for institutional limited partners.
- Kurma Diagnostics II (KDx2) An €83 million healthtech-focused venture fund, the only investment vehicle wholly dedicated to financing early-stage European innovative medical diagnostic companies, with a focus on deeptech firms specializing in disruptive molecular diagnostic tools. Intended for institutional limited partners.
- Kurma Biofund III A €160 million therapeutic venture fund, the third in Kurma's Biofund series, focused on life sciences investments from pre-seed to growth stages. Intended for institutional limited partners.
- Paris Saclay Seed Fund An early-stage seed fund associated with the Paris Saclay ecosystem, focused on financing innovative healthcare and biotech startups originating from the Paris Saclay research cluster. Intended for portfolio companies and co-investors.
- Argobio Studio A French biotech startup studio created in partnership with Bpifrance, Kurma Partners, Angelini Pharma, Evotec, and Institut Pasteur, aiming to create at least five high-potential biotechnology companies over five years with €50 million in initial funding. Targeted at academic researchers and entrepreneurs seeking to build biotech companies.
Companies that use Kurma Partners
Customer profileSegments3 records
Ideal customer profiles4 records
Kurma Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Kurma Partners partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Samsung BiologicscoreStrategic partnership for development and manufacturing of biologics for Kurma's portfolio companies. Samsung Biologics to provide derisking, development, manufacturing services and seamless transitions for biologics from early stages of development to large scale commercialisation. The partnership streamlines gene to IND process to accelerate lead candidate selection.
- Institut PasteurcoreKey academic partner for company creation, including PathoQuest and other companies
- Inserm TransfertcoreAcademic research partner in the network
Scale indicators6 records
Recent moves4 records
Expansion highlights5 records
Kurma Partners competitors and assessment
Company assessmentDirect peers
- HealthCap: Nordic-European specialist biotech VC investing across stages. Comparable in mandate, stage range, and orientation toward therapeutic company creation.
- Sofinnova Partners: Paris-based European healthcare and biotech VC with a multi-stage strategy spanning early-stage company creation to growth. Directly comparable in mandate, stage focus, and European geographic footprint.
- Forbion: Leading European biotech VC managing multiple fund vehicles across development stages. Comparable as a specialized life-sciences investor with similar AUM scale and pan-European deal sourcing.
- Andera Partners: Paris-based European healthcare and biotech investor. Direct peer — co-invested with Kurma in Adcytherix and Alveus Therapeutics and operates a similar Life Sciences strategy.
- Jeito Capital: European healthcare-focused VC led by Sabine Dandiguian, investing in biotech across development stages. Directly comparable in stage range and European focus, and a co-investor with Kurma in Alveus Therapeutics.
- Omega Funds: Boston-based healthcare and biotech investment firm with global mandate. Comparable as a specialist life-sciences investor; co-led the Alveus Therapeutics Series A alongside Kurma's participation.
- Wellington Partners: European life-sciences and technology VC. Comparable as a multi-stage European healthcare investor and recurring co-investor with Kurma in NUCLIDIUM.
Broad incumbents
- Novo Holdings: Holding company of the Novo Nordisk Foundation managing multi-billion healthcare and biotech investments globally. Comparable as a large-scale healthcare investment platform; participated in Alveus Therapeutics alongside Kurma.
- Bpifrance: French sovereign investment bank with large healthcare and biotech investment operations. Comparable as a major French life-sciences investor and recurring co-lead/lead (Adcytherix) and cornerstone LP (Biofund IV) of Kurma.
Emerging players
- Pureos Bioventures: European biotech VC investing in private early-stage drug development companies. Comparable in stage focus and therapeutic orientation, and a co-investor with Kurma in Adcytherix.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Kurma Partners social profiles
Digital presenceKurma Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kurma Partners leadership team
Management profileNumber of profiles
Profiles8 records
Kurma Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kurma Partners M&A and investment
M&A and investmentM&A
Investments131 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kurma Partners
What does Kurma Partners do?
Kurma Partners is a Paris-based venture capital firm that finances healthcare and biotechnology innovation in Europe across the company lifecycle, from academic spin-out creation through growth capital. It manages multiple specialized fund vehicles (therapeutic Biofund series, Diagnostics franchise, Growth Opportunities Fund) totaling approximately €1 billion in assets under management, and operates the Argobio Studio startup launchpad in partnership with leading European research institutions to build biotech companies from scientific discoveries.
Is Kurma Partners a public or private company?
Kurma Partners is a private company. It is classified as corporate owned and is currently operating.
When was Kurma Partners founded?
Kurma Partners was founded in 2009. It employs 11 to 50 people.
Where is Kurma Partners based?
Kurma Partners is headquartered in Paris, France, in the Europe region.
Who are Kurma Partners's main competitors?
Direct peers on record are HealthCap, Sofinnova Partners, Forbion, Andera Partners, Jeito Capital, Omega Funds and Wellington Partners. Broad incumbents are Novo Holdings and Bpifrance. Pureos Bioventures is listed as an emerging player.
Does Kurma Partners have an API?
No public API is recorded for Kurma Partners.
What industry is Kurma Partners in?
Kurma Partners's product category is Venture Capital - Healthcare and Biotechnology. Its primary akta.pro industry code is FSANAHAC, Corporate Venture Studios & Incubators (Build/launch ventures), with a secondary code of FSANAHAE, Joint Venture CVC / Consortium Funds (Multi-corporate). Its NAICS code is 525 and its SIC code is 6282.